Day: March 10, 2026

Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000

CHICAGO, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated...

Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000

CHICAGO, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated...

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly...

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly...

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

A German CDO Supporting Biotech Companies Bringing Biologics from Early Development to ClinicMELBOURNE, Australia, March 10, 2026 (GLOBE NEWSWIRE) --...

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

A German CDO Supporting Biotech Companies Bringing Biologics from Early Development to ClinicMELBOURNE, Australia, March 10, 2026 (GLOBE NEWSWIRE) --...

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sitesPotential first and only pharmacological...

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sitesPotential first and only pharmacological...

UPDATED – Moving from Pledge to Production, Clover Health is Now Live on Kno2, Participating in Recently Announced Federal Interoperability Initiatives

Clover Health's early adoption of real-time patient access to claims data on Kno2 is made possible by underlying infrastructure powered...

error: Content is protected !!